{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T16:12:07Z","timestamp":1795104727955,"version":"4.10.3"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ijantimicag.2024.107341","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T02:07:54Z","timestamp":1726711674000},"page":"107341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["In-vitro activities of essential antimicrobial agents including aztreonam\/avibactam, eravacycline, colistin and other comparators against carbapenem-resistant bacteria with different carbapenemase genes: A multi-centre study in China, 2021"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3906-398X","authenticated-orcid":false,"given":"Yun","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2024.107341_bib0001","series-title":"Antibiotic resistance threats in the United States 2019","year":"2019"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0002","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0003","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1080\/22221751.2020.1799721","article-title":"Prevalence, risk factors and molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in patients from Zhejiang, China, 2008\u20132018","volume":"9","author":"Hu","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0004","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/cid\/ciab295","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0005","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0006","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00472-17","article-title":"In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015","volume":"61","author":"Karlowsky","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0007","article-title":"In vitro activities of aztreonam-avibactam, eravacycline, cefoselis, and other comparators against clinical Enterobacterales isolates: a multicenter study in China, 2019","volume":"11","author":"Chen","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.micres.2022.127249","article-title":"Global spread of carbapenem-resistant Enterobacteriaceae: epidemiological features, resistance mechanisms, detection and therapy","volume":"266","author":"Ma","year":"2023","journal-title":"Microbiol Res"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0009","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1080\/22221751.2020.1754133","article-title":"Colistin and its role in the era of antibiotic resistance: an extended review (2000\u20132019)","volume":"9","author":"El-Sayed Ahmed","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0010","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0119-2022","article-title":"New antibiotics for Gram-negative pneumonia","volume":"31","author":"Bassetti","year":"2022","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0011","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.3390\/biomedicines11071784","article-title":"In vitro activity of eravacycline against carbapenemase-producing Gram-negative bacilli clinical isolates in central Poland","volume":"11","author":"Brauncajs","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0012","article-title":"In vitro activity of eravacycline against Gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0013","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"2024"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0014","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1080\/22221751.2021.1948804","article-title":"Novel tigecycline resistance mechanisms in Acinetobacter baumannii mediated by mutations in adeS, rpoB and rrf","volume":"10","author":"Hua","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0015","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2024"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0016","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1080\/22221751.2022.2093134","article-title":"Epidemiological and genetic characteristics of clinical carbapenem-resistant Acinetobacter baumannii strains collected countrywide from hospital intensive care units (ICUs) in China","volume":"11","author":"Liu","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0017","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02839-23","article-title":"Clinical and molecular epidemiology of carbapenem-resistant Enterobacteriaceae in pediatric inpatients in South China","volume":"11","author":"Xiong","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0018","article-title":"Carbapenem-resistant Pseudomonas aeruginosa infections in critically ill children: prevalence, risk factors, and impact on outcome in a large tertiary pediatric hospital of China","volume":"11","author":"Huang","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0019","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1473-3099(19)30755-8","article-title":"Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study","volume":"20","author":"van Duin","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0020","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/cid\/ciad556","article-title":"Clinical outcomes and bacterial characteristics of carbapenem-resistant Acinetobacter baumannii among patients from different global regions","volume":"78","author":"Wang","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0021","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(21)00399-6","article-title":"Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study","volume":"22","author":"Wang","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0022","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1517\/14656566.2015.973851","article-title":"Treatment strategies for central nervous system infections: an update","volume":"16","author":"Tan","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0023","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ijid.2020.07.050","article-title":"In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula","volume":"99","author":"Sonnevend","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0024","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/22221751.2022.2048972","article-title":"Carbapenemase-producing Pseudomonas aeruginosa \u2013 an emerging challenge","volume":"11","author":"Tenover","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.909731","article-title":"What is new in the anti-Pseudomonas aeruginosa clinical development pipeline since the 2017 WHO alert?","volume":"12","author":"Reig","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0026","series-title":"Highlights of prescribing information","year":"2020"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0027","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1080\/14787210.2022.2128764","article-title":"Treatment strategies for OXA-48-like and NDM producing Klebsiella pneumoniae infections","volume":"20","author":"Isler","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2024.107341_bib0028","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/antibiotics8030122","article-title":"Present and future of carbapenem-resistant Enterobacteriaceae (CRE) infections","volume":"8","author":"Suay-Garc\u00eda","year":"2019","journal-title":"Antibiotics (Basel)"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924002577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924002577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T10:55:05Z","timestamp":1730717705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857924002577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0924857924002577"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107341","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In-vitro activities of essential antimicrobial agents including aztreonam\/avibactam, eravacycline, colistin and other comparators against carbapenem-resistant bacteria with different carbapenemase genes: A multi-centre study in China, 2021","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107341","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107341"}}